Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination antiparasitic therapy consisting of tinidazole (a nitroimidazole antibiotic) and albendazole (a benzimidazole antiparasitic). This combination is primarily used for treating persistent parasitic infections, particularly **giardiasis**, that have failed to respond to conventional monotherapy [2]. It leverages the complementary antiparasitic mechanisms of both drugs. **Tinidazole** works by disrupting the DNA of susceptible organisms [7]. It is effective against protozoa like _Giardia_, _Trichomonas_, and _Entamoeba_ [4][6][9]. **Albendazole** primarily inhibits microtubule formation in parasites, affecting various helminthic infections (like tapeworms, hookworms) and also effective against protozoa like _Giardia_ [1][3]. When combined, they have shown enhanced effectiveness in treating refractory **giardiasis** after conventional treatment failure [2]. Combination therapy studies have demonstrated clinical cure in such patients [2]. The combination is generally well-tolerated. Side effects can include gastrointestinal disturbances, bitter taste, and nausea, with tinidazole potentially causing more side effects than albendazole [3][5][7][10]. Both should be avoided with alcohol due to the risk of disulfiram-like reactions [3][10]. This combination is particularly useful where first-line treatments fail, nitazoxanide is unavailable, or when co-infections with other sensitive parasites are present [2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tinidazole + albendazole.